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Background: Small fiber neuropathy (SFN) is commonly associated with sarcoidosis and can
cause significant morbidity to afflicted patients. The appropriate treatment of this condition,
when associated with sarcoidosis, is not well established.
Methods: Descriptive case series of three patients with sarcoidosis and SFN. The presenting
clinical features, skin biopsy results, autonomic reflex screen and quantitative sudomotor axon
reflex testing (QSART) findings, and response to therapy are delineated.
Results: We describe three patients with biopsy-proven sarcoidosis who developed intractable
neuropathic pain and/or symptoms related to associated autonomic dysfunction despite treat-
ment with various immunosuppressive medications and narcotic analgesics. QSART showed
evidence of a postganglionic sudomotor abnormality in one patient and was normal in the other
two. Skin biopsy findings were abnormal, demonstrating a non-length-dependent sensory SFN
in all three patients. Painful neuropathic symptoms, as well as symptoms related to dysauto-
nomia from SFN responded significantly to treatment with intravenous immunoglobulin (IVIG).
Conclusion: IVIG appears to be effective in relieving symptoms from SFN associated with
sarcoidosis, suggesting an underlying immune mechanism. Larger prospective, controlled
studies would be needed to confirm this response to IVIG and to further elucidate the under-
lying pathobiology behind this association with sarcoidosis.
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Sarcoidosis is a multi-system immune-mediated disorder of
unknown etiology characterized by the formation of non-
necrotizing granulomas in affected organs.1 Neurologic
involvement from granulomatous inflammation in sarcoidosis
occurs inapproximately5%ofpatientsandhasbeendescribed
toaffect virtually anypartof thecentral orperipheralnervous
system, and most commonly includes cranial neuropathies,
meningeal disease, and parenchymal mass lesions.2
Recently, small fiber neuropathy (SFN), a neuropathy
that selectively involves small-diameter myelinated and
unmyelinated nerve fibers has been recognized to affect
over 40% of patients with sarcoidosis.3,4 The treatment of
this entity with commonly used medications for systemic
sarcoidosis including corticosteroids and other immuno-
suppressants has generally been disappointing and have not
been found to be useful.5
In this series we describe the clinical features, findings
from various neurologic diagnostic tests, and the response to
IVIG of refractory neuropathic pain and of symptoms from
dysautonomia due to SFN in three patients with sarcoidosis.
Methods
Skin biopsy
Three 3-mm skin punch biopsy specimens were obtained;
10 cm proximal to the lateral malleolus, the lateral prox-
imal thigh, and at the lateral distal thigh. Obtained speci-
mens were fixed in 2% periodateeparaformaldehydeelysine
(PLP)esucrose, cryoprotected in 20% glycerol, sectioned at
50-mm, and then immunostained using the polyclonal rabbit
anti-human protein gene product (PGP) 9.5 antibody.
Immunostaining signals were developed using the Vecta SG
peroxidase substrate chromogen kit (ABC; Vector Labs,
Burlingame, CA). The quantification of the number of small
nerve fibers was then established using an image analysis
system and confocal microscopy by one of us (LZ). In
controls the normal number of intra-epidermal nerve fiber
density (IENFD) has been determined at 21.1 10.4 per
millimeter in the thigh and 13.8 6.7 per millimeter at the
distal part of the leg.6,7
Quantitative sudomotor axon reflex testing
(QSART)
Quantitative sudomotor axon reflex test (QSART) is used to
evaluate postganglionic sympathetic cholinergic sudomotor
function by measuring the axon reflex mediated sweat
response over time. Sweat glands are stimulated by ionto-
phoresis of a cholinergic agent and the sweat production is
measured as an increase of humidity through a hygrom-
eter.8 Retrieved data were reviewed by two of us (JT, LZ)
and normal values for QSART are displayed in Table 1.
Autonomic reflex screen (ARS) testing
Besides evaluating the autonomic reflex patterns of sudo-
motor function by QSART, a battery of autonomic testswere used to evaluate adrenergic and cardiovagal
responses. The Valsalva ratio and the heart rate response to
deep breathing were used to evaluate cardiovagal function.
The blood pressure and heart rate response to head-up tilt
table testing and the beat-to-beat blood pressure response
to the Valsalva maneuver were used to evaluate adrenergic
function.
Small fiber neuropathy screening list (SFNSL) score
The SFN screening list developed by Hoitsma et al. was used
as an objective instrument for assessments of response of
symptoms to the therapeutic trials of IVIG.9 A series of 21
questions were used to create the SFNSL questionnaire and
a total score was made for the SFNSL by summing the scores
of the 21 questions (Table 2). Utilizing temperature
threshold testing (TTT) to assess the function of small-
caliber sensory fibers, Hoitsma and colleagues identified
a cut-off score of <11 on the SFNSL as indicative of normal
TTT and a cut-off score of >48 as indicative of an abnormal
TTT. A score range from 11 to 48 indicated a group of
patients in which a third had normal TTT and two-thirds had
abnormal TTT.9
The Cleveland Clinic Foundation Institutional Review
Board approved this study and patients authorized the use
of their medical records for research.
Results
All three patients were screened for large-fiber neuropathy
with nerve conduction studies (NCS) and electromyography
(EMG), which were normal. All patients had normal vitamin
B12 and thyrotropin levels and no evidence of HIV infection,
anti-nuclear antibodies and/or extractable nuclear anti-
gens, or monoclonal paraproteinemia. Results of a 2-h
glucose tolerance test did not show diabetes mellitus or
impaired glucose tolerance either. All three also underwent
quantitative evaluations of the humoral immune system
with measurements of serum immunoglobulin levels and of
specific antibody titers after immunization against both
polysaccharide and protein vaccines and results did not
identify an underlying immunodeficiency disorder.
Patient 1
A 27-year-old woman presented with a 9-month history of
progressive peripheral pain of her lower extremities,
hands, chest, and lower back, sicca symptoms, palpita-
tions, and orthostatic intolerance. She was diagnosed with
sarcoidosis 12-months prior to the onset of these symptoms
by mediastinoscopy for stage II chest radiographs that
showed non-necrotizing granulomatous lymphadenitis.
Besides symptomatic pulmonary involvement, she also had
anterior uveitis along with ulcerative and maculopapular
skin lesions consistent with cutaneous sarcoidosis. Therapy
with tapering doses of oral corticosteroids and 10-mg of
methotrexate resulted in improvement of her respiratory,
ocular, and cutaneous disease. However, she started to
notice the above-mentioned symptoms that progressed
despite increasing doses of oral corticosteroids and
methotrexate.
Table 1 Normal values for quantitative sudomotor axon reflex test (QSART).
Site Latency (min) Sweat output (ml/cm2)
Forearm 1:30e3:30 Male: >0.76
Female: >0.20
Proximal leg 0.50e2:20 Male: >0.93
Female: >0.36
Distal leg 0:50e2:20 Male: >0.98
Female: >0.61
Proximal foot 1:20e2:30 Male: >0.78
Female: >0.23
Sarcoidosis 103When she came to see us, she had disabling peripheral
pain with hyperalgesia managed with 60-mg of controlled
release morphine sulfate and 450-mg of pregabalin. She
also had several episodes of palpitations on a daily basis,
some associated with near-syncope. Her SFNSL score was
63. Perfusionemetabolism positron-emission-tomographic
(PET) scanning of the heart did not suggest cardiac
sarcoidosis and event monitoring showed only sinus tachy-
cardia. ARS testing was consistent with postural orthostatic
tachycardia syndrome with her heart rate rising from
a baseline of 110 beats-per-minute (bpm) to 160 bpm within
3 min without systemic hypotension. QSART was normal
while skin biopsy showed a non-length-dependent SFN with
severe reduction in IENFD in the proximal thigh, distal
thigh, and distal leg to 2.3 fibers/mm, 3.4 fibers/mm, and
2.3 fibers/mm, respectively.Table 2 Small fiber neuropathy screening list (SFNSL).9
N
PART 1: How often are the following complaints experienced
1. I have painful arms ,
2. I suffer from palpitations ,
3. I have problems with my bowel movements ,
4. I have difficulties with urinating ,
5. My food does not go down well ,
6. I suffer from muscle cramps ,
7. My feet and/or hands are colder than I am used to ,
8. I have chest pain ,
PART 2: How serious the complaints are
9. I feel that food gets stuck in my throat ,
10. At night I throw the bedclothes off my legs ,
11. I have difficulties with urinating ,
12. I have dry eyes ,
13. I have blurred vision ,
14. I feel dizzy when I get up ,
15. I have sudden hot flushes ,
16. My feet and/or my hands are colder than I am used to ,
17. I have painful arms ,
18. The skin of my legs is over-sensitive ,
19. I have tingling sensation in my hands ,
20. I have tingling sensation in my legs ,
21. I have chest pain ,
Reproduced with permission from the ILD care foundation ª (Ref.9, p.
questionnaire online: http://www.ildcare.nl/index.php?idZ100 (http
PDF or online version).She received IVIG 2-g/kg initially, followed by 1-g/kg in
2-weeks, and then continued with 1-g/kg administered
every 4-weeks. Within four weeks, she reported significant
improvement in peripheral pain with cessation of need for
analgesics, resolution of sicca symptoms, decrease in
episodes of palpitations to brief (<1-min) episodes once
monthly, and return of orthostatic tolerance. By three
months, her SFNSL score improved to 10. She was tapered
off oral corticosteroids and at 12-months she was on
methotrexate and 0.75-g/kg of IVIG every 3-weeks.
Patient 2
A 48-year-old woman presented with a 5-month history of
progressively worsening numbness, tingling, and disabling
pain of her face, hands, legs, feet, and chest. Theseever Sometimes Fluctuating Often Always
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frequent nocturnal awakenings from painful sheet intoler-
ance, clumsy hands, palpitations with orthostatic dizziness,
absence of genital sensitivity, chronic nausea, and irregular
bowel movements with a predominance of constipation. She
was diagnosed with sarcoidosis 4-years prior to the onset of
these symptoms when she presented with chronic sinusitis
and sinus biopsy showed non-necrotizing granulomatous
sinusitis. Besides sinonasal disease, she also had symptom-
atic stage II pulmonary disease and chronic sarcoid arthrop-
athy. Despite the weekly use of subcutaneous methotrexate
20-mg, she required high doses of daily oral corticosteroids
(40-mg prednisone) to mainly help control her upper
respiratory disease. Therefore, 7-months prior to the onset
of her SFN symptoms, she was initiated on intravenous
infliximab 3-mg/kg, repeated in 2-weeks and continued
every 6-weeks. With this there was significant control of her
multi-organ sarcoidosis and allowed the tapering off of oral
corticosteroids. However, she started to notice the above-
mentioned symptoms that progressed despite increasing
the dose and changing the frequency of infliximab 4-months
prior to her visit to out institution to 5-mg/kg and every
4-weeks, respectively, and re-instituting high doses of oral
corticosteroids.
On her initial visit with us, she was wheelchair bound
from disabling pain. Her SFNSL score was 74. PET scanning
of the heart did not suggest cardiac sarcoidosis and event
monitoring only showed sinus tachycardia. ARS testing
showed an attenuated cardiovagal baroreflex and an
elevated cardiovascular adrenergic abnormality; she was
diagnosed with the syndrome of inappropriate sinus
tachycardia. Gastric emptying studies suggested gastro-
paresis. QSART was normal and skin biopsy showed a severe
non-length-dependent SFN with absent IENFD in the distal
leg. In the proximal thigh IENFD were reduced at 2.8 fibers/
mm, while IENFD were 7.3 fibers/mm in the distal thigh and
showed qualitative changes of axonal swelling, increased
branching, and uneven distribution of epidermal axons.
She was treated with IVIG 2-g/kg followed by 1-g/kg in 2-
weeks, and then received maintenance doses of 1-g/kg
every 4-weeks. Upon re-evaluation in three months, she
was walking without assistance and demonstrated signifi-
cant improvement of her SFNSL score to 12 along with
resolution of peripheral neuropathic symptoms, absence of
palpitations with no further evidence of sinus tachycardia
on Holter monitoring, and return of genital sensation. Her
nausea improved to being noticed mildly on days of meth-
otrexate injection, and her bowel movements became
regular. At 20-months she was off corticosteroids and
remained on methotrexate and infliximab and continued
with 0.75-g/kg of IVIG every three weeks.
Patient 3
A 42-year-old man old presented with a 6-month history of
severe burning pain associated with numbness and tingling
of his hands, feet, forearms, legs, and chest. This was
associated with profuse sweating, patchy hair loss on his
legs and forearms, episodic flushing of his hands, face and
feet, erectile dysfunction, and cold intolerance. He was
diagnosed with sarcoidosis by mediastinoscopy 2-years prior
when he presented with symptoms suggestive of Lo¨fgren’ssyndrome. Resected specimens showed non-necrotizing
granulomatous lymphadenitis.
When he came to see us, he had excruciating peripheral
pain temporized with 1800-mg of gabapentin, 100-mg of
amitriptyline, and 80-mg of controlled release oxycodone.
His SFNSL score was 43. QSART showed reduced sweat
production in the forearm at 0.34 ml/cm2, absence of
sweat in the proximal foot, and normal sweat output in the
leg suggestive of SFN. Skin biopsy showed a non-length-
dependent SFN with absence of IENFD in the proximal thigh
and reductions of IENFD in distal thigh and distal leg to 1.8
fibers/mm and 3.5 fibers/mm, respectively.
Based on the case report of successful response of
symptomatic SFN related to sarcoidosis to infliximab by
Hoitsma and colleagues,10 he was initiated on this at 3-mg/
kg, repeated at 2-weeks and continued every 6-weeks.
Despite receiving four months of biologic therapy, he still
had severe pain and now used crutches to ambulate. At this
time he began to notice episodes of orthostatic dizziness,
some associated with near-syncope and his SFNSL score
increased to 55. Cardiac PET scans were normal, event
monitoring only showed sinus bradycardia, and ARS testing
showed an enhanced cardiovagal baroreflex along with
cardiac adrenergic failure.
He was subsequently initiated on IVIG 2-g/kg followed by
1-g/kg in 2-weeks, and then received maintenance doses of
1-g/kg every 4-weeks. Upon re-evaluation in three months,
he was now walking without assistance and demonstrated
improvement in his SFNSL score to 9 along with resolution
of peripheral pain, absence of orthostatic intolerance with
normal heart rate and rhythm on Holter monitoring, and
return of erectile function. At nine months he remained
on infliximab 3-mg/kg every 6-weeks and continued with
0.75-g/kg of IVIG every 3-weeks.Discussion
Sarcoidosis is considered a T-cell mediated multi-system
disease with the lungs as the main target of this disorder
and characterized by the presence of non-necrotizing
granulomas in affected organs.1,11 The mechanisms behind
this disease are not completely known but have been
identified as a highly polarized T-helper 1 (Th1) immune
response mediated by a complex network of lymphocytes,
macrophages, and cytokines.1,11,12
SFN has increasingly been recognized as an organic basis
for peripheral neuropathic pain and dysautonomia in
sarcoidosis and has been described to affect over 40% of
patients.3,4 This type of neuropathy has been associated
with many medical conditions, and while most of these
cause a length-dependent SFN, others, most notably Sjo¨g-
ren’s syndrome and celiac disease, can cause a form of SFN
that is not length-dependent.4,13 In this small series, all
three patients displayed a sensory SFN that was not length-
dependent.
While treatment of systemic sarcoidosis usually includes
corticosteroids and other immunosuppressants such as
methotrexate, these agents have not been found to be
useful in relieving SFN related to sarcoidosis, similar to
our patients.5 Recently, Hoitsma and colleagues described
the dramatic response of symptomatic SFN related to
Sarcoidosis 105sarcoidosis in one patient to infliximab therapy.10 In our
series though, SFN symptoms developed in one patient on
infliximab therapy and progressed despite 4-months of
infusions in another patient.
Intravenous immunoglobulin (IVIG) has been reported to
be effective in two patients with peripheral large-fiber
neuropathy associated with sarcoidosis; one with chronic
inflammatory demyelinating polyneuropathy and the other
with predominantly sensory axonal polyneuropathy.14,15
There have however been no reports on the response of
SFN associated with sarcoidosis to IVIG infusions.
IVIG has also been reported to be effective in the treat-
ment of one patient and three patients with SFN related to
Sjo¨gren’s syndrome and celiac disease, respectively.16,17
Interestingly, both these disorders have been shown to
cause a form of SFN that is not length-dependent,4,13 similar
to all three patients in our series. Because of the efficacy of
IVIG therapy a direct immune-mediatedmechanismhas been
proposed in the pathogenesis of non-length-dependent
SFN.16,17 The precise mechanisms by which an infusion of
polyclonal IgG exerts an immunomodulatory effect are not
yet known.16,18 Various humorally mediated mechanisms
have been suggested including neutralization and clearance
of circulating immune complexes and autoantibodies, satu-
ration and functional blockage of Fc receptors on macro-
phages, binding activated complement components, and
functional modulation of T-cells.18,19,20
Our small series suggests that IVIG appears to be effec-
tive in relieving symptoms from SFN associated with
sarcoidosis. This significant response argues for an under-
lying immune mechanism that may be occurring indepen-
dent of local site-specific disease activity. Regardless of
what these underlying mechanisms may be, larger
prospective controlled studies would be needed to confirm
this response to IVIG as commonly prescribed immunosup-
pressive treatments for systemic sarcoidosis have not been
found to be useful in relieving SFN related to sarcoidosis. If
confirmed to be beneficial from these larger studies,
questions regarding finer aspects of this therapy can be
addressed as well, including optimal dose, effective dosing
interval, and cost-effectiveness.
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